We found that intrathecal injection of rosiglitazone reduced the mechanical hyperalgesia induced by bone cancer by activating PPAR-γ to inhibit the NF-κB/NLRP3 inflammatory axis in spinal cord neurons. This evidence concerns the gene NFKB1 and bone neoplasm.